Periodic Reporting for period 4 - CAREMIBRAIN (A new brain-dedicated Positron Emission Tomography (PET) system to identify β-amyloid biomarker for the early diagnosis of Alzheimer’s disease and other causes of cognitive decline)
Reporting period: 2019-06-01 to 2020-08-31
Only 1-in-4 people with AD have been diagnosed.
For the fast ageing populations of the Western societies, AD is becoming one of the main public health concerns, associated with a social and economic burden, and the provision of care for people with AD is a complex and costly issue.
At present, there is not any therapy that can effectively cure the disease since it is a complex disorder of which the exact cause is still not known.
Given that AD is the highest ticket health and social care item that we have, making up 60% of long term care spending according to some estimates, then targeted investment in early intervention and in research (into causes, cure and care) are likely to be of major value in personal, societal, political, and economic terms.
This brain-dedicated Positron Emission Tomography (PET) tackles some of the key issues highlighted by the European initiative on Alzheimer’s disease, especially those related to early diagnoses of Alzheimer’s disease, improved understanding of dementias and good practices with regard to diagnosis, treatment and financing of therapies for these conditions.
CareMiBrain, the ONCOVISION’s new brain-dedicated PET—which is going to be validated, produced and commercialised in this innovation project—solves the stated problem in the following way:
a) PATIENT will:
• Allow an early detection of AD and other causes of cognitive decline: early planning and assistance, help in the management of other symptoms which may accompany the early stage of AD, and rule out reversible and treatable causes of dementia. It also offers more opportunities to participate in clinical trials, some involving new drugs which could be more effective. Non-drug intervention can also delay and slow progression, provides time to record memories, and offers caregivers more understanding and patience, qualifying for disability if still working. Besides, it provides time to identify and address safety concerns, become informed about what to expect, and benefits for support groups.
• Facilitate the treatment efficacy tracking.
• Use a lower radiotracer dose to the patient.
b) HEALTH SYSTEM will:
• Reduce costs of PET equipment as this new system will cost up to 3 times less than whole-body PET systems.
• Reduce costs of hospital facilities as our brain-dedicated PET needs smaller rooms with lower construction costs.
c) SOCIETY will:
• Contribute to reduce societal cost per patient slowing the evolution of AD and maintaining the patient with mild symptoms as long as possible.
The main objectives of this project are to market an innovative brain-dedicated PET system to facilitate the early diagnosis of Alzheimer’s disease (AD) and other causes of cognitive decline.
The expected outcomes of this project are the clinical validation and commercialisation of a new PET system that will push the resolution to the physical limit, while increasing its sensitivity three times with respect to current whole-body PET systems; and offering a competitive price, three times lower than other whole-body PET systems developed by large manufacturers.
This system could be also used in different clinical situations to support the assessment of other critical neurological disorders different from AD (or conditions related to cognitive decline), as epilepsy, brain tumour, local neuroinflammation, cerebral ischemia or phobias.
Therefore, this brain-dedicated PET needs smaller and, for that reason, cheaper hospital facilities to perform its diagnostic function. Other advantage related to its high sensitivity is the need of a lower radiotracer dose that has an impact on reduced tracer cost and less radiation to the patient.
The new system has passed the electromagnetic compatibility and electrical safety trials according to rigorous international standards for medical devices.
The documentation of fabrication/QA and validation of the calibration and manufacturing tools are almost complete taking advantage of the manufacture of Unit 4. Most of the CE Mark dossier has also been created.
Clinical trials have suffered a delay caused by the COVID-19 health crisis. With the situation returning slowly to the normal status, the 4 institutions are ready to start. Oncovision is carrying out the last Ethical Committees requirements in order to be able to send the devices and start the Clinical Studies, paused by the already mentioned health crisis caused by COVID-19. This delay has allowed us to work in technical developments to improve the reconstruction software.
During the last period an amendment of the GA has been approved with these three major changes:
- Time extension
- Changes in the budget to implement a mitigation plan of some of the problems caused by the health crisis
The project has not been able to implement an intensive participation in international events, due to the health crisis. Our efforts are moving to improve its visibility in Internet and the social networks.
A high resolution and sensitivity, small footprint and reduced cost dedicated brain PET will make the brain imaging more affordable to many institutions, allowing to perform this important diagnostic instrument to more patients.
The high sensitivity of the system will permit to reduce the radiactive dose to the patient, the cost of the radiotracer and the acquisition time.
A brain PET imaging more accessible and safe, will aim to early diagnoses of Alzheimer’s disease, improved understanding of dementias and good practices regarding diagnosis, treatment and financing of therapies for these conditions.